ATR-12
Netherton Syndrome
Phase 1Active
Key Facts
About Azitra
Azitra is a clinical-stage biopharmaceutical company focused on developing precision dermatology treatments by engineering the skin's native microbiome. Its core strategy utilizes a proprietary platform combining a large microbial library, AI/ML screening, and genetic engineering to create live biotherapeutic products and engineered proteins. The company's lead program, ATR-12, targets the rare disease Netherton syndrome, with a pipeline extending to oncology supportive care and common dermatoses.
View full company profileTherapeutic Areas
Other Netherton Syndrome Drugs
| Drug | Company | Phase |
|---|---|---|
| QRX003 (via Quoin Pharmaceuticals) | Skinvisible Pharmaceuticals | Clinical Trials |
| Pipeline Program | MatriSys Bioscience | Preclinical |
| SXR1096 | Sixera Pharma | Phase 1 |
| KB104 | Krystal Biotech | Preclinical |
| BCX17725 | BioCryst Pharmaceuticals | Pre-Clinical/Phase 1 |
| QRX003 | Quoin Pharmaceuticals | Phase 2/3 |